

- Biological basics (*continued*)**
- cell nutrients, 46-52
    - growth media, 52
    - macronutrients, 48, 49-50
    - micronutrients, 48, 50-51
  - microbial diversity, 11-12
    - aerobic organisms, 11-12
    - anaerobic organisms, 11-12
    - bacillus, 12
    - coccus, 12
    - extremophiles, 12
    - facultative organisms, 12, 53
    - mesophiles, 11
    - psychrophiles, 11
    - spirillum, 12
    - thermophiles, 11
  - procaryotes, 15-19
    - archaeabacteria, 17-19
    - eubacteria, 15-17
  - viruses, 14-15
- Biological engineering, 2**
- Biological films, 266-68**
- defined, 266
  - schematic representation of, 268
  - thickness of, 267-68
- Biological oxygen demand (BOD), 489-90**
- BOD removal, 493, 503
- Biological waste treatment, 488-508**
- advanced waste-water treatment systems, 501-8
  - defined, 489
  - overview, 488-91
  - primary treatment, 491
  - processes, 491-501
    - activated-sludge processes, 491-95
    - anaerobic digesters, 499-501
    - oxidation ponds, 499
    - rotating biological contactors (RBC), 498-99
    - trickling biological filters, 496-98
  - secondary treatment, 491
  - sludge, 491
  - tertiary treatment, 491
  - waste-water carbon content, 489-90
  - waste water, conversion to useful products, 506-8
- Bioluminescence, 128**
- Biomedical engineering, 2**
- Biomolecular engineering, 2**
- Biopharmaceutical products, 423**
- Biopolymers, 25-26**
- Bioprocess engineer, 1-10**
- bioprocess engineering, 2
- bioprocess regulatory constraints, 8-10**
- biotechnology, 2**
- penicillin, 3-8
  - research approach, 3
- Bioprocess engineering, defined, 2**
- Bioprocess engineering medical applications, 463-74**
- bioreactors, 471-72**
- extracorporeal artificial liver, 472
  - stem cells and hematopoiesis, 471-72
- gene therapy using viral vectors, 467-71**
- retro virus, mass production of, 470-71
  - viral infection models, 467-70
- tissue engineering, 463-66**
- chondrocyte culture for cartilage replacement, 465-66
  - commercial tissue culture processes, 465-66
  - compared to protein production from mammalian cells, 464
  - defined, 463-64
  - tissue-engineered skin replacements, 465
- Bioprocess regulatory constraints:**
- FDA drug approval process, 9
  - good laboratory practices (GLP), 9
  - good manufacturing practice (GMP), 9
  - guideline updates, 9-10
  - standard operating procedures (SOPs), 9
- Bioreactors, 285-328, 471-72**
- for animal cell cultures, 396-400
  - cleaning, 291
  - in continuous cultivation, 189-99
  - cultivation methods, 387-96
  - data logging, 311
  - extracorporeal artificial liver, 472
  - height-to-diameter ratio, 297
  - immobilized cell systems, 263-75, 285
  - instrumentation for measurements of active fermentation, 307-11
  - mixed cultures, 487-508
  - for plant cell cultures, 411-17
  - for plant cells, 407
  - scale-up, 286-306
    - reactor types, 286-92
  - stem cells and hematopoiesis, 471-72
  - and sterility, 291
  - sterilization, 291, 314-23
  - stirred-tank reactor, 286, 288
  - suspension cultures, 408-9, 410, 411-13
- Biosynthesis, 145-48**
- Biotin, 51**